Navigation Links
Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment
Date:12/20/2011

igenexpress.com/">www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced it received ... H, a hemp-based, advanced headache relief product, for planned ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... 8, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... year 2010 financial results before the NASDAQ Global Select Market ... Lief, Arena,s President and Chief Executive Officer, will host a ... Time) to discuss the financial results for the fourth quarter ...
... Sciences: OTC Bulletin Board: RBCL ) -- RBC ... care and pain management products, today reported a 13% increase ... ended December 31, 2010, compared to net sales of $24.9 ... Company reported net earnings of $558,000, or $0.02 per diluted ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 3RBC Life Sciences Reports Sales and Earnings Growth in 2010 2RBC Life Sciences Reports Sales and Earnings Growth in 2010 3
(Date:12/26/2014)... December 26, 2014 “Many people become ... personal injury claim issues and phone calls with insurance ... an article featuring their free eBook on pedestrian ... eBook on pedestrian and bicycle auto accident claims assures ... fully capable of professionally handling their case while they ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... Recently, BellasDress has launched its ... dresses. BellasDress has chosen their best-selling lace wedding dresses, ... the holiday season. , Now, BellasDress.com features popular ... here at discount prices. The business hopes everyone can ... , “All our elegant products are made ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... childhood cancers are current smokers, and nearly a third have ... to a study in the July 29 online issue of ... , Adult survivors of childhood cancer are at increased risk ... to the general public. These increased risks are due to ...
... $0.56 Net Income Per Share, SAN JOSE, Calif., ... ), a leading provider of medical devices,for the minimally ... for the second quarter ended June 30, 2008., ... 85% to $31.9,million compared with $17.2 million for the ...
... grocery purchases to loyal ... pharmacy customers, ... a new pharmacy loyalty program which will,reward frequent pharmacy customers with ... will receive a 10 percent discount,coupon after every five prescriptions filled ...
... to offer new therapeutic option for ... ... today announced that the,Arthritis Advisory Committee of the U.S. Food ... approval of ACTEMRA(R),(tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal,antibody, for ...
... recall rate for abnormal mammograms was lower in Norwegian practice ... -- The typical U.S. breast cancer screening strategy results ... approach use in Norway, but both are equally good at ... the July 29 online issue of the Journal of ...
... NEW YORK, July 29 Dr. Jamie Sands, DDS, ... says a lot about who you are,it shouldn,t say ... Pro-Health, Oral-B Vitality powered toothbrush and Crest Glide Floss,can ... from Crest at:, http://media.medialink.com/WebNR.aspx?story=35391 ), Registered journalists ...
Cached Medicine News:Health News:1/5 of British adult survivors of childhood cancer smoke despite hazards 2Health News:1/5 of British adult survivors of childhood cancer smoke despite hazards 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:Jewel-Osco Launches 'Prescription Plus' Discount Program 2Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 2Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 3Health News:FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis 4Health News:2 Breast Cancer Screening Strategies Prove Effective 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: